Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
691
Regulation of Food Intake01:30

Regulation of Food Intake

3.0K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.0K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

7.8K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.8K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.8K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Frameworks for Diagnostic Decision-Making in AI-Enhanced Head and Neck Pathology.

Head and neck pathology·2026
Same author

Adhesion index integrates cell and bacterial responses to titanium across protein conditioning and surface roughness.

Biofilm·2026
Same author

Characterization of the circular RNA landscape of human dorsal root ganglia reveals a neurotrophin-related circRNA is modulated by opioid exposure.

Pain·2026
Same author

Integrating virtual patient-based learning into temporomandibular disorder education improves educational and behavioral outcomes.

BMC medical education·2026
Same author

Doxazosin Alleviates Chronic Orofacial Pain.

International journal of molecular sciences·2026
Same author

Salivary Biomarker Panel That Identifies Periodontitis in Persons With Type 2 Diabetes: A Secondary Analysis of a Cross-Sectional Study.

Journal of clinical periodontology·2025

Related Experiment Video

Updated: Mar 2, 2026

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.1K

PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Danielle N Lyons1, Liping Zhang, Robert J Danaher

  • 1Departments of *Physiology, College of Medicine †Oral Health Practice, University of Kentucky, Lexington, KY.

The Clinical Journal of Pain
|May 18, 2017
PubMed
Summary

Peroxisome proliferator-activated receptor-gamma (PPARγ) activation reduces trigeminal neuropathic pain. This nuclear receptor plays a key role in pain transmission, offering a potential therapeutic target for orofacial pain.

More Related Videos

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

49.5K
Author Spotlight: Utilizing Infraorbital Nerve Ligation in Mice for Investigating Trigeminal Neuropathic Pain and Treatment Strategies
05:38

Author Spotlight: Utilizing Infraorbital Nerve Ligation in Mice for Investigating Trigeminal Neuropathic Pain and Treatment Strategies

Published on: March 8, 2024

3.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.1K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

49.5K
Author Spotlight: Utilizing Infraorbital Nerve Ligation in Mice for Investigating Trigeminal Neuropathic Pain and Treatment Strategies
05:38

Author Spotlight: Utilizing Infraorbital Nerve Ligation in Mice for Investigating Trigeminal Neuropathic Pain and Treatment Strategies

Published on: March 8, 2024

3.0K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Trigeminal neuropathic pain is a debilitating condition.
  • The role of nuclear receptors in pain pathways is an area of active research.

Purpose of the Study:

  • To investigate the role of peroxisome proliferator-activated receptor-gamma (PPARγ) in trigeminal neuropathic pain.
  • To utilize a novel mouse trigeminal inflammatory compression (TIC) injury model to study pain mechanisms.

Main Methods:

  • Localized PPARγ immunoreactivity in the spinal trigeminal nucleus following TIC injury.
  • Administered PPARγ agonist pioglitazone (PIO) and antagonist GW9662 in a mouse model.
  • Assessed mechanical allodynia to evaluate pain response.

Main Results:

  • PPARγ immunoreactivity increased in the spinal trigeminal caudalis 3 weeks post-TIC injury.
  • Systemic PIO administration attenuated mechanical allodynia in a dose-dependent manner.
  • GW9662 blocked the analgesic effects of PIO, confirming PPARγ's role.

Conclusions:

  • PPARγ plays a significant role in trigeminal nociception transmission.
  • Activation of PPARγ attenuates hypersensitivity in a mouse model of trigeminal neuropathic pain.
  • Pioglitazone, an FDA-approved drug, may serve as a therapeutic agent for orofacial pain by targeting PPARγ.